Pegunigalsidase alfa

Pegunigalsidase alfa, sold under the brand name Elfabrio, is an enzyme replacement therapy for the treatment of Fabry disease.[1][3] It is a recombinant human α-galactosidase-A.[3] It is a hydrolytic lysosomal neutral glycosphingolipid-specific enzyme.[1]

Pegunigalsidase alfa
Clinical data
Trade namesElfabrio
Other namesPRX-102, pegunigalsidase alfa-iwxj
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC2060H3130N552O601S27
Molar mass46110.58 g·mol−1

The most common side effects are infusion-related reactions, hypersensitivity and asthenia.[3]

Pegunigalsidase alfa was approved for medical use in both the European Union and the United States in May 2023.[3][2]

Medical uses

Pegunigalsidase alfa is indicated for long-term enzyme replacement therapy in aduls with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).[1][3]

Society and culture

On 23 February 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Elfabrio, intended for the treatment of Fabry disease.[3] The applicant for this medicinal product is Chiesi Farmaceutici S.p.A.[4][5] Elfabrio was approved for medical use in the European Union in May 2023.[3]

References
  1. "Elfabrio- pegunigalsidase alfa injection, solution, concentrate". DailyMed. 23 May 2023. Retrieved 24 May 2023.
  2. "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 9 May 2023. Archived from the original on 21 January 2023. Retrieved 12 May 2023.
  3. "Elfabrio EPAR". European Medicines Agency. 8 May 2023. Archived from the original on 10 May 2023. Retrieved 9 May 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. "Elfabrio: Pending EC decision". European Medicines Agency. 23 February 2023. Archived from the original on 24 February 2023. Retrieved 25 February 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  5. "Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease" (Press release). Chiesi Global Rare Diseases. 24 February 2023. Archived from the original on 24 February 2023. Retrieved 25 February 2023 – via PR Newswire.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.